Daniel S. Goldman sold Biomarin Pharmaceutical Inc (NASDAQ: BMRN)
Daniel S. Goldman (D-NY), a U.S. Representative, has disclosed 1 trade in Biomarin Pharmaceutical Inc (BMRN) since 2023, a single sale, worth an estimated $8K in disclosed volume (the midpoint of the dollar ranges members report, not exact amounts).
The trade highlighted here is a sale: Daniel S. Goldman sold $1,001 - $15,000 of Biomarin Pharmaceutical Inc (NASDAQ: BMRN) on March 6, 2023. Since that trade, BMRN is down -35.76% against the S&P 500 up +91.29%, an outperformance of -127.04%.
Data updated
Daniel S. Goldman's BMRN trades vs the price
BMRN is down -35.76% since Daniel S. Goldman sold on March 6, 2023, versus +91.29% for the S&P 500.
Performance since this trade
All Daniel S. Goldman BMRN trades
Daniel S. Goldman & BMRN trading FAQ
Is it legal for Daniel S. Goldman to trade Biomarin Pharmaceutical Inc (BMRN) stock?
Yes. Members of Congress are allowed to trade individual stocks, including Biomarin Pharmaceutical Inc (BMRN), but the STOCK Act of 2012 requires them to publicly disclose each transaction within 45 days. Quantellect tracks those disclosures; this page does not imply the trade was improper.
When did Daniel S. Goldman sell BMRN?
Daniel S. Goldman disclosed a sale of $1,001 - $15,000 of Biomarin Pharmaceutical Inc (BMRN) on March 6, 2023, according to public STOCK Act filings.
How has BMRN performed since Daniel S. Goldman's trade?
Since Daniel S. Goldman sold BMRN on March 6, 2023, the stock is down -35.76%, versus +91.29% for the S&P 500 over the same period, an outperformance of -127.04%.
How soon must members of Congress disclose a trade?
Under the STOCK Act, members of Congress must publicly report a covered transaction within 45 days of the trade. Filings can still be delayed, amended, or contain errors.
Where can I see all congressional BMRN trades?
Quantellect tracks every disclosed congressional trade in Biomarin Pharmaceutical Inc (BMRN) on the Biomarin Pharmaceutical Inc congressional trading page, which aggregates filings across all members of Congress.
Daniel S. Goldman's BMRN tradesAll congressional filings for Biomarin Pharmaceutical IncDaniel S. Goldman's full profile
Not investment advice. Congressional trading data is sourced from public STOCK Act disclosures, which are filed with a delay and may contain errors or be revised. Estimated prices and post-trade returns are derived algorithmically from public filings and end-of-day market data and describe historical activity, not a recommendation. Always do your own research and consult a licensed financial advisor before making investment decisions.